Explore every episode of the podcast All Things Cardio-Oncology

Dr. Eric Chow is an expert in cancer survivorship. He focuses on survivors of childhood cancers and survivors of blood stem cell transplantation of all ages. In this discussion he addresses the various cardiovascular challenges survivors of childhood cancer face.

Kathryn J. Ruddy, M.D., studies long-term and late effects of cancer treatments, and how to best care for cancer survivors to enhance their quality of life and reduce symptoms. In this episode Dr. Ruddy discusses her session at the ACC meeting on cardioprotective strategies.

Anecita Fadol who is Associate Professor, Education Director- Nursing Cardiology Program · The University of Texas MD Anderson Cancer Center and chair of the ICOS nurses Working Group

Jessica Coviello, DNP, APRN(Ct), ANP-BC, FAAN, Associate Dean of Faculty Development, Professor, Graduate Studies, Univ of TX School of Nursing in Houston

Dr. Carrie Lennemam, University of Alabama Birmingham explains how they are using AI to expedite referrals to their cardio-oncology clinic, saving time and saving lives.

Dr. Eric Yang, Director of Cardio-Oncology discusses how they have integrated cardio-oncology training into all aspects of their program for residents and fellows.

Dr Zsofia Drobni is a Cardiology Fellow at Semmelweis University, Budapest, HU. Her research focuses on the utility of cardiac CT and MRI in patients receiving cardiotoxic therapies, with a specific focus on immune checkpoint inhibitors. Dr Drobni graduated in 2017 from Semmelweis University, in Hungary, and continued her PhD studies at Semmelweis. Her PhD thesis was on “new perspectives of CT-based cardiovascular risk assessment”. From 2019, Dr Drobni was a research fellow at the Cardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard University. Dr Drobni is currently the president of and founded the Hungarian Chapter of IC-OS.

Dr Prince Otchere, MD, MPH is an Assistant Professor at the University of Texas Health where he co-directs the cardio-oncology programme. He is working with physicians in Ghana to create a National Cardio-Oncology Society and is also helping develop cardio-oncology programmes in two teaching hospitals in Ghana. His research interest involves creating and refining cardiac risk prediction models to anticipate patients who are at risk of cardiotoxicity.

Watch Full Webinar Here:

https://www.radcliffecardiology.com/webinars/cardiac-risk-prediction-model-patients-her-2-positive-breast-cancer-trastuzumab-therapy#

Read Dr. Otchere's award winning paper here:

https://cardiooncologyjournal.biomedcentral.com/articles/10.1186/s40959-023-00177-y

Dr Tamar Polonsky (The University of Chicago, US), explores the implications, diagnostic strategies and potential interventions for addressing incidental atherosclerosis in the journey of cancer care.

Watch Full Webinar Here:

https://www.radcliffecardiology.com/webinars/approach-incidental-atherosclerosis-cts-cancer-patients

Dr. Eiman Jahangir

Associate Professor of Medicine

Division of Cardiovascular Medicine

Director, Cardio-Oncology

Vanderbilt University Medical Center

In this episode Dr. Janhangir describes how he was selected to fly with Blue Origin to sub-orbital space fulfilling a lifelong dream. We also discuss the intersection of his work as a physician with his background in space science and the humanities.

Dr. Hyeon-Ju Ali Assistant Professor, Department of Cardiology,, MD Anderson Cancer Center, Houston, TX discusses her research and experience in a complex and challenging area of clinical care.

Read more on this subject:

Chronic thromboembolic pulmonary hypertension suspicion after pulmonary embolism in cancer patients

https://www.sciencedirect.com/science/article/abs/pii/S2590041219300248

Mechanical Venous Thrombectomy for Deep Venous Thrombosis in Cancer Patients: A Single-Center Retrospective Study

https://link.springer.com/article/10.1007/s00270-024-03691-3

Among other things Dr. Lang and Dr. Dan Lenihan discuss blood pressure treatments for patients with cancer.

For more information on the work Dr. Lang and his team are engaged in see: https://www.gla.ac.uk/schools/cardiovascularmetabolic/research/cardiac-diseases/oncology/#publications

Dr. Thavendiranathan discusses the HIMILAYAS trial, looking at exercise interventions for cancer survivors and the STOPMEDCTRCD trial addressing the ongoing efficacy of continuing use of cardiovascular medicines after cancer therapy

Dr. Paaladinesh Thavendiranathan is a cardiologist at the Toronto General Hospital, University Health Network; Associate Professor of medicine at the University of Toronto and a Clinician Investigator.

Learn more about the HIMILAYAS trial here:
https://www.himalayastrial.ca/
Learn more about the STOPMEDCTRCD trial here:
https://classic.clinicaltrials.gov/ct2/show/NCT06183437

Darryl Leong is a leading researcher in genitourinary malignancies including prostate, bladder and renal cancers. The cardiovascular risks and complications for each are varied depending on the treatments involved. Dr. Leong discusses the risk profiles and management strategies for this population.

Dr. Neilan discusses the largest randomized trial in the ICI therapy space, the ATRIUM trial.

Tom Neilan, MD, MPH Director, Cardio-Oncology Program
Co-Director, Cardiac MR PET CT Program

Learn more about the ATRIUM trial here:
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04887

Karlis Trusinskis, MD President of IC-OS Latvia chapter speaks about the challenges and opportunities of cardio-oncology care in his country.

Diego Sadler, MD

Section Head Cardio Oncology, Cleveland Clinic Florida

In this episode Dr. Sadler speaks about his pioneering work with the Global Cardio-Oncology Registry. This is the first in kind registry that aims to enroll cardio-oncology patients from around the world. GCOR is a multinational, multicenter prospective observational cohort registry and will collect clinical, laboratory, imaging, demographic and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular disease.

Dr. Anju Nohria is the Director of the Cardio-Oncology Program at Dana-Farber Brigham Cancer Center and a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH). In addition, she is an Assistant Professor of Medicine at Harvard Medical School (HMS).

On this episode she discusses the challenges and opportunities of starting a new clinic focused on cardio-oncology care.

Renato Lopes, MD, PhD, FACC

Renato Delascio Lopes

Professor of Medicine

Duke University, School of Medicine

Professor of Medicine Divisions of Internal Medicine and Cardiology, Federal University of Sao Paulo, Sao Paulo, Brazil

Dr. Lopes discusses his ongoing efforts to develop, produce, and distribute cardio-oncology education in Brazil and the United States.  

Dr Vivek Narayan is an Assistant Professor of Medicine at Hospital of the University of Pennsylvania, Philadelphia, US.

View the entire webinar here:
https://www.radcliffecardiology.com/video-index/renal-cell-carcinoma-and-vegf-tki-cardiovascular-toxicity

Richard Cheng MD, MSc. is cardiology faculty at the University of Washington, Seattle, with a focus in cardiomyopathies, cardio-oncology and cardiac imaging. He is Program Director for the HF fellowship and the Director of the Cardio-oncology Program. He has formal training with a Masters-in-Science in clinical trial design and biostatistics. He has extensive editorial experience, including serving on the editorial boards for JACC, JACC: Cardio-oncology, JHLT, and is an associate editor for Heart (BMJ). Additionally, he is topic (section) editor for cardiomyopathies for ACC/HFSA HFSAP and an associate editor for ACC.org for heart failure and cardiomyopathies. His research focus over the last several years has been on risk stratification in heart failure, cardiac amyloidosis, and cardio-oncology cohorts.

Read the full manuscript here:

https://heart.bmj.com/content/early/2024/01/24/heartjnl-2023-323502

Donate to the Rachel Levine Amyloidosis Awareness Fund here:

https://ic-os.info/RachelDaraLavineFund

Dr Saro Armenian is a Pediatric Hematologist-Oncologist at City of Hope's (COH) main campus Duarte, US. He co-leads the COH Cancer Control and Population Sciences Program and directs the Center for Survivorship and Outcomes in the Hematologic Malignancies Research Institute.

https://www.radcliffecardiology.com/video-index/cardiovascular-considerations-patients-undergoing-stem-cell-transplantation

Dr Michelle Kittleson is Professor of Medicine at Cedars-Sinai and Director of Education in Heart Failure and Transplantation at the Smidt Heart Institute. She graduated from Harvard College and received her medical degree from Yale University. She completed residency training at Brigham and Women's Hospital and cardiology fellowship at Johns Hopkins, where she also received a PhD in Clinical Investigation.

Watch the complete webinar here: https://www.radcliffecardiology.com/webinars/latest-clinical-trial-updates-attr-cm-and-al-cm

Dr. Paul Cottu, oncologist at Institut Curie, Paris, FR provides an overview of breast cancer therapies with associated cardiovascular toxicities. The original webinar can be viewed at the link below:

https://www.radcliffecardiology.com/webinars/cardiotoxicity-breast-cancer-challenges-multimodal-therapies

In this new series we will be highlighting the patient experience by speaking with patients and the physicians who treat them. We know you will be inspired by these stories in your own experience either as a patient or a health care provider.

Today we speak withLalitha C. Medepalli, MD, FACC, FASE, RPVINorthside Hospital, Atlanta, GA USA and her patient Karen Rowland.

Dr Anne Blaes is a Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the Director of the Screening, Prevention, Etiology, and Cancer Survivorship (SPECS) Program within the Masonic Cancer Center. 

View the original webinar here:

https://www.radcliffecardiology.com/webinars/applying-esc-ic-os-guidelines-how-do-we-actually-do-risk-stratification

Ihab Rafic Hamzeh, MD, Associate Professor, Department of Cardiology, The MD Anderson Cancer Center, Houston, TX

This is a highlight from our weekly webinar January 11, 2023. You can view the entire broadcast at the link below.

https://www.radcliffecardiology.com/webinars/cardiovascular-toxicities-novel-cancer-drugs

Dr Kathryn Ruddy is a Professor of Oncology at Mayo Clinic, Rochester, US. She co-leads the Prevention, Survivorship and Care Delivery Programme at Mayo Clinic Comprehensive Cancer Center.

Dr. Ganatra and Dr. Daniel Lenihan discuss an article they both contributed to titled "SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction"

Article Link

⁠https://www.sciencedirect.com/science/article/abs/pii/S2213177923005966⁠

Dr. Sarju Ganatra is Vice Chair of the Department of Medicine at Lahey Hospital Department of Medicine Research

Follow him on X:

@SarjuGanatraMD

Dan Lenihan and Steve Casselli had a chance to sit down with Dr. Prince Otchere at the San Antonio Breast Cancer Summit 2023 and discuss developments in Ghana, Africa which Prince is helping to pioneer.

We had the chance to sit down with Dr. Icro Meattini from Florence, Italy to hear about his experience as a Radiation Oncologist from Italy along with his insights about the SABCS meeting.

Dr. Susan Dent, Dr. Teresa Lopez-Fernandez speak with IC-OS Executive Director Steve Casselli about community highlights from the past year.

This is a brief discussion recorded at the American Heart Association in Philadelphia, USA.

Teresa López-Fernández is a clinical investigator and consultant cardiologist at La Paz University Hospital in Madrid, Spain. She is specializes in cardiac imaging and cardio-oncology (she is board certified by the International Cardio-Oncology Society), and currently coordinates the cardio-oncology team at La Paz University Hospital.

Dr. Joseph Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center.

He is also an editor of the Cardio-Oncology Journal. For submission information and to read the latest science go to: https://cardiooncologyjournal.biomedcentral.com/

Dr. Michael Fradley speaks about the role of electrophysiology in cardio-oncology from the American Heart Association meeting in Philadelphia, USA.

Dr Alessandra Ferrajoli (University of Texas MD Anderson Cancer Center, US) provides an in-depth cumulative review of hypertension management in patients with Chronic Lymphocytic Leukemia (CLL) and other hematologic malignancies treated with Acalabrutinib. This podcast explores the mechanisms, incidence and clinical implications of treatment-related hypertension, offering evidence-based strategies to optimise cardiovascular care for this patient population.

Dr. Abdelrahman Ali, Cardio-Oncology Fellow speaks with Dr. Daniel Addison and Dr. Daniel Lenihan at the AHA meeting in Philadephia about Dr. Addison's presentation on health equity.

Juan Lopez-Mattei is Medical Director and Director of Cardiac Imaging, Lee Health Heart & Vascular Institute,

Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS)

https://pubmed.ncbi.nlm.nih.gov/36216699/

Delegates from around the world share their reflections from the 2022 GCOS meeting in Toronto, Canada October 5-7 including: Kerry Skurka, RN (USA), Trent Williams, RN (Australia), Christine Brezden-Masley, MD (Canada), Stefanie Mundnich, MD (Chile), Ana Barac, MD (USA), Dan Gilon, MD (Israel), Zaza Iakobishvili, MD (Israel), Edith Pituskin, PhD (Canada), Anecita Fadol, PhD (USA), Giselle Melendez, MD (USA), Juliana Salas Segura, MD (Costa Rica), Alex Lyon, MD (United Kingdom), Karlis Trusinskis, MD (Latvia), Trishun Singh, MD (South Africa),  Susan Dent, MD (USA), Teresa Lopez-Fernandez (Spain)

We had the opportunity to speak with Dr. Eric Yang and Dr. Daniel Addison at the annual American Heart Association meeting in Philadelphia, USA about using biomarkers for risk stratification.

Thanks to Dr. Abdelrahman Ali, Cardio-Oncology Fellow at MD Anderson for assisting us in this episode.

Dr. Cezar Iliescu

Professor, Department of Cardiology, and an Interventional Cardiologist, The University of Texas MD Anderson Cancer Center, Houston, TX

Related Articles:

RECURRENT MALIGNANT PERICARDIAL EFFUSION

https://www.jacc.org/doi/abs/10.1016/S0735-1097(22)02882-0

Halloween in the Cath Lab

https://pubmed.ncbi.nlm.nih.gov/31501856/

Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis

https://www.frontiersin.org/articles/10.3389/fcvm.2022.916325/full

Dr. Giovanni Palladini

Associate Professor of Clinical Chemistry

The University of Pavia, Pavia, IT

Discusses the challenges and clinical symptoms for diagnosing AL Amyloidosis

Dr. Kasey Leger, Associate Professor of Pediatrics

Seattle Children’s & University of Washington

She leads the Children’s Oncology Group Myeloid Cardiotoxicity taskforce and the cardiac aims imbedded in the ongoing Phase 3 COG trial evaluating cardioprotective strategies and cardiotoxicity predictors in de novo pediatric AML

Dr. Will Border

Chief Physician Wellness Officer | Children’s Healthcare of Atlanta

Director of Noninvasive Imaging | Children’s Healthcare of Atlanta Cardiology

Professor of Pediatrics | Emory University School of Medicine

October 26, 2023 Pediatric Cardio-Oncology Virtual Summit, registration and more information here: https://members.ic-os.org/events/register.aspx?id=1778866

Dr. Daniel Lenihan, Saint Francis Healthcare System, Cape Girardeau, US

Dr. Giovanni Palladini, Associate Professor of Clinical Chemistry The University of Pavia, Pavia, IT

Dr. Richard Cheng, Associate Professor of Medicine/Cardiology and Radiology, University of Washington, Seattle, US

Dr. Ashutosh Wechalekar, senior lecturer and honorary consultant haematologist, University College London and the Royal Free London NHS Foundation Trust, UK

Discuss promising new therapies for AL Amyloidosis

Joshua Mitchell, MD, MSCI is an Assistant Professor of Medicine and Co-Director of the Amyloid Center of Excellence at Washington University School of Medicine in St. Louis.  He also serves as the Director of the Cardio-Oncology Center of Excellence and Cardio-Oncology Fellowship.

RESOURCES:

Original Webinar: https://www.radcliffecardiology.com/video-index/ic-os-weekly-webinar-evaluation-and-management-cardiotoxicity-radiation-therapy

Related Article: Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the

International Cardio-Oncology Society

https://www.jacc.org/doi/10.1016/j.jaccao.2021.06.003

Tomas G. Neilan, MD, MPH discusses the broad spectrum of biomarkers that can be used to detect ICI mediated myocarditis.

Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, a cardiologist at MGH, the director of the Cardio-Oncology Program at MGH and the co-director of the Cardiovascular Imaging Research Center. He holds the Michael and Kathyrn Park Chair in Cardiology. He is a physician scientist and a board-certified cardiologist. He completed his medical school training at University College Dublin Medical School, his clinical training in Internal Medicine and Cardiology at the Mater Hospital in Dublin and repeated his training in Internal Medicine and Cardiology at MGH. He has also competed advanced training in echocardiography at MGH, a clinical and research fellowship in cardiac MRI at BWH, and a Master’s in Public Health at the Harvard School of Public Health. His career has had two major focuses: 1) Understanding how we can improve the cardiovascular care of patients with cancer and 2) The use of advanced imaging to better understand and characterize cardiovascular disease. He has authored or co-authored more than 150 original manuscripts, 40 review articles, has presented over 400 abstracts at international meetings, and has lectured at major national and international meetings. Dr. Neilan has been awarded the “de Gunzburg Family Endowed Scholar in Cardiology”, The Locke Award for excellence in medical education and elected as a Senior Fellow to the Oliver Wendell Holmes Society at Harvard Medical School.

Dr. Barac and Dr. Bloom were authors on a new scientific statement from the Heart Failure Society of America on Cardio-Oncology. In this episode they discuss highlights from this statement.

Dr. Ana Barac serves as the Medical Director of the Cardio-Oncology Program at Inova Health in Fairfax. VA in the Wash DC area. She is a Professor of Medicine at Georgetown University and her interests focus on advanced cardiovascular imaging.

Dr. Bloom is a professor in the Department of Medicine and a member of the Division of Cardiology at NYU Grossman Long Island School of Medicine.

A renowned expert in cardio-oncology and heart failure, she joined New York University Langone Health as director of the Cardio-Oncology Program in 2023.

Dr. Rebecca Roylance Consultant Medical Oncologist and Honorary Associate Professor at University College London Hospital

Dr. Andrew Wilson Consultant Hematologist and honorary associate professor at University College London Hospital

Andrew and Rebecca discuss clinical management of patients and how they collaborate with their cardiology colleagues in daily practice.

Dr. Nicolas Palaskas surveys emerging therapies for treating immune checkpoint inhibitor myocarditis, a rare but life threatening condition.

Nicolas Palaskas MD is an Assistant Professor of Medicine in the Department of Cardiology. Dr. Palaskas completed cardiology fellowship (2017) and internal medicine residency (2014) at Baylor College of Medicine. He joined MD Anderson Cancer Center in 2017 immediately following completion of fellowship. His clinical interests include cancer therapeutic cardiotoxicity management, echocardiography, and cardiac catheterization for patients with cancer. In addition, Dr. Palaskas leads institutional efforts in immunotherapy cardiotoxicity. His main research focus is on immune checkpoint inhibitor-related myocarditis for which he has three grants related to the diagnosis and surveillance of myocarditis; Cancer Prevention & Research Institute of Texas Early Clinical Investigator Award (2020), Sabin Family Foundation Fellowship (2020), and Division of Internal Medicine Research Development Award (2019).

Watch the whole webinar here:

https://wondrmedical.net/ch/IC-OS/videos/Ic-Os-Weekly-Webinar-Immune-Checkpoint-ED84B7881

In this episode we speak with the Chair of the IC-OS Center of Excellence Certification Committee Dr. Vijay Rao who explains the history, rationale and benefits of becoming an IC-OS Center of Excellence.

Dr. Rao completed his MD and PhD at the Medical University of South Carolina, Internal Medicine residency at Duke University Medical Center, followed by Cardiology fellowship at the University of California, San Francisco.  He is the Director of the CardioOncology, Heart Failure, and Anticoagulation clinics at Franciscan Health in Indianapolis, Indiana.  He serves as Chair of the IC-OS Center of Excellence Committee and is an active member of the IC-OS education committee.  The Franciscan CardioOncology program won the Association of Community Cancer Centers (ACCC) national Innovator Award in 2019 and was selected as an IC-OS Center of Excellence: Gold Status in 2022.  He was also the lead author on a JACC: State of the Art Review on Cardiovascular Toxicity of Oral Antineoplastic Agents in 2021 and is the Governor-Elect of the Indiana Chapter of the American College of Cardiology. 

Darryl Leong is a Scientist at PHRI, Director of the McMaster University and Hamilton Health Sciences Cardio-Oncology Program, Associate Professor, Department of Medicine (Cardiology), McMaster University, and Staff Cardiologist at Hamilton Health Sciences. He has methodological expertise in clinical epidemiology and clinical trials, and content expertise in physical frailty, echocardiography, and cardio-oncology.